Adjunctive probiotics after periodontal debridement versus placebo: a systematic review and meta-analysis

Authors

  • Ethan Ng a Discipline of Periodontics, Faculty of Dentistry, National University of Singapore, Singapore; b Department of Restorative Dentistry, National Dental Centre Singapore, Singapore
  • John Rong Hao Tay a Discipline of Periodontics, Faculty of Dentistry, National University of Singapore, Singapore; b Department of Restorative Dentistry, National Dental Centre Singapore, Singapore
  • Seyed Ehsan Saffari c Health Services and Systems Research, Duke-NUS Medical School, Singapore
  • Lum Peng Lim a Discipline of Periodontics, Faculty of Dentistry, National University of Singapore, Singapore
  • Kong Mun Chung a Discipline of Periodontics, Faculty of Dentistry, National University of Singapore, Singapore
  • Marianne Meng Ann Ong b Department of Restorative Dentistry, National Dental Centre Singapore, Singapore; d Oral Health Academic Clinical Programme, Duke-NUS Medical School, Singapore

DOI:

https://doi.org/10.1080/00016357.2021.1942193

Keywords:

Lactobacillus, Bifidobacterium, periodontitis, periodontal debridement, host-modulation

Abstract

Objective

To comprehensively investigate the efficacy of adjunctive probiotics compared to placebo, using conventional and novel treatment outcomes.

Materials and methods

Three databases (MEDLINE, EMBASE, and CENTRAL) were searched. Outcomes included percent change in the total number of deep sites before and after therapy, change in mean probing pocket depth (mm), percentage patients requiring additional therapy, risk for disease progression, and microbiological and immunological results. Meta-analysis was conducted to evaluate treatment effects wherever appropriate.

Results

Ten studies were selected from 818 records. Meta-analysis showed that adjunctive probiotics had no additional benefit for percentage change of the total number of deeper sites (≥5 mm, ≥6 mm, ≥7 mm) before and after therapy. No significant difference was observed for mean probing pocket depth reduction at 3 and 6 months. Statistically significant beneficial odds ratios for need for additional therapy (OR = 0.19, 95% CI [0.07–0.56]) and risk of disease progression (OR = 0.32, 95% CI [0.14–0.73]) were observed with probiotic administration. Immunological rather than microbiological outcomes correlated more consistently with clinical findings. No adverse events were reported.

Conclusions

Adjunctive probiotics are safe in systemically healthy individuals and could offer additional patient-level benefits compared to placebo, hence its use can sometimes be justified.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2022-02-17